SKP2 and posterior cortical atrophy: These studies suggest a novel strategy in which a combined inhibition of SKP2 and AR (or PI3K/AKT and AR) pathways may improve the efficacy for treatment of PCa including castration-resistance PCa (CRPC), particularly in the context of PTEN loss.